Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1696 • ACR Convergence 2025
A multi-omics resource of B cell activation reveals genetic mechanisms for autoimmune diseases
Vitor Aguiar¹, Marcella Franco¹, Nada Abdel Aziz¹, Daniela Fernandez-Salinas², Marcos Chinas¹, Mariasilvia Colantuoni², Qian Xiao¹, Nicolaj Hackert¹, Yifei Liao³, Rodrigo Cervantes-Diaz¹, Marc Todd¹, Brian Wauford¹, Alex Wactor¹, Vaishali Prahalad¹, Raquel Laza-Briviesca¹, Roxane Darbousset¹, Qiang Wang¹, Scott Jenks⁴, Kevin Cashman⁴, Esther Zumaquero⁴, Zhu Zhu¹, Junning Case³, Paloma Cejas⁵, Miguel Munoz-Gomez⁵, Hannah Ainsworth⁶, Miranda Marion⁷, Mehdi Benamar¹, Pui Lee⁸, Lauren Henderson⁹, Margaret Chang², Kevin Wei¹⁰, Henry Long⁵, Carl Langefeld¹¹, Benjamin Gewurz³, Ignacio Sanz⁴, Jeffrey Sparks¹², Esra Meidan¹³, Peter Nigrovic² and Maria Gutierrez-Arcelus², ¹Boston Children's Hospital, Boston, ²Boston Children's Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, ⁴Emory University, Atlanta, ⁵Dana Farber Cancer Institute, Boston, ⁶Wake Forest University, Winston-Salem, NC, ⁷Wake Forest, Winston-Salem, ⁸Boston Children's Hospital, Newton, MA, ⁹Boston Children's Hospital, Watertown, MA, ¹⁰Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ¹¹Wake Forest University School of Medicine, Winston Salem, NC, ¹²Brigham and Women's Hospital, Boston, MA, ¹³Boston Children's Hospital, Somerville, MA
Background/Purpose: Most genetic variants that confer risk of complex autoimmune diseases affect gene regulation in specific cell types. Their target genes and focus cell types…
Abstract Number: 1550 • ACR Convergence 2025
Real-World Outcomes of Anifrolumab in Systemic Lupus Erythematosus Patients at Toronto Lupus Program
Virginia Carrizo Abarza¹, Qixuan Li², Teresa Semalulu³, Justin Smith³, Pankti Mehta⁴, Fadi Kharouf⁵, Dafna D. Gladman⁶, Laura Whitall Garcia⁷ and Zahi Touma³, ¹Toronto Western Hospital - University of Toronto, Toronto, ON, Canada, ²Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Gladman Krembil Psoriatic Arthritis Research Program, Toronto, ON, Canada, ⁵University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁷University Health Network, Toronto, ON, Canada
Background/Purpose: Anifrolumab (ANI) is a human monoclonal antibody targeting the type I interferon receptor subunit 1 (IFNAR1), blocking interferon activity and reducing disease activity in…
Abstract Number: 1532 • ACR Convergence 2025
Preliminary Safety, Efficacy, and Cellular Kinetics of CTA313, a CD19/BCMA Dual-Targeted Universal CAR-T Therapy, for Active Systemic Lupus Erythematosus
Hanwei Wang¹, Yue Xie², Guojiao Yang³, Lu Han³, Jiangtao Ren⁴, Yali Zhou⁴, Wengang Ge³, Jan Davidson-Moncada⁴ and Huan Zhou⁵, ¹The Third People’s Hospital of Bengbu, Beng bu, China (People's Republic), ²Bioheng Therapeutics Limited, Nan Jing Shi, China (People's Republic), ³Bioheng Therapeutics Co., Limited, Nanjing, China (People's Republic), ⁴Bioheng Therapeutics Co., Limited, Nan Jing, China (People's Republic), ⁵Clinical Research Hospital of the First Affiliated Hospital of Anhui Medical University, Hefei, China (People's Republic)
Background/Purpose: SLE is characterized by B cell activation, autoantibody production and autoreactivity. Recently, CAR-T therapy has emerged as a promising strategy to deplete autoreactive B…
Abstract Number: 1512 • ACR Convergence 2025
Anti-U1-RNP Antibody Positivity is Associated with Elevated Interferon Score in SLE Irrespective of Disease Activity: A Transcriptome Analysis in Japanese Patients
Takemichi Matsui¹, Yumi Tsuchida², Takahiro Itamiya², Mineto Ota², Toshihiko Komai², Haruka Tsuchiya², Hirofumi Shoda², Tomohisa Okamura² and Keishi Fujio², ¹Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: With the introduction of anifrolumab to clinical practice, there is a growing interest in identifying factors associated with IFN activity in patients with SLE.…
Abstract Number: 1489 • ACR Convergence 2025
Impact of Menopause on Long-Term Outcomes in Patients with Systemic Lupus Erythematosus
Lorena López, José Bretón and Luis Vilá, University of Puerto Rico Medical Sciences Campus, San Juan, PR
Background/Purpose: Women of childbearing age are more prone to developing autoimmune diseases, suggesting a role for sex hormones, particularly estrogens, in regulating both cellular and…
Abstract Number: 1472 • ACR Convergence 2025
Characteristics and Predictors of LLDAS in Survivors of Early Active Lupus: Insights from a Decade-Long Cohort
Amirtha Gopalan¹, keerthi vardhan yerram², Mahesh Gaikwad² and Liza rajasekhar³, ¹Nizams Institute of Medical Sciences, Hyderabad, Hyderabad, Telangana, India, ²Nizams institute of medical sciences, hyderabad, Andhra Pradesh, India, ³Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: LLDAS is a desirable state in lupus, with ongoing global reports on its durability and outcomes. The relationship between LLDAS, baseline characteristics, and drug…
Abstract Number: 1284 • ACR Convergence 2025
Clinical implications of Antiphospholipid Antibodies and Secondary Antiphospholipid Syndrome in Juvenile-onset Systemic Lupus Erythematosus
Daniel Clemente¹, Alina-Lucica Boteanu², Clara Udaondo³, Joan Calzada⁴, Juan Carlos Nieto⁵, Eugenia Enriquez⁶, Inmaculada Calvo⁷, Lourdes Villalobos⁸, Belen Sevilla⁹, Sara Murias¹⁰, Berta Magallares¹¹, Ana Capilla¹², Jaime Arroyo¹³, Beatriz Bravo¹⁴, Gisela Diez-Cordoves¹⁵, Marisol Camacho¹⁶, Genaro grana¹⁷, Juan Jose Bethencourt¹⁸, Pablo Mesa¹⁹, Natalia Palmou²⁰, Mireia Lopez Corbeto²¹, Judith Sanchez²², Maria Isabel Gonzalez²³, Clara Moriano²⁴, Diego Dios¹⁷, Lorena Exposito²⁵, Alicia Garcia²⁶, Laura Martin²⁷, David Fernandez²⁸, Laura Trujillo¹⁴, Anahy Maria Brandy²⁹, CARLOS GUILLEN-ASTETE³⁰ and lydia Abasolo Alcazar³¹, ¹Hospital Infantil Universitario NIño Jesús, Madrid, Madrid, Spain, ²H.U. Ramón y Cajal, Madrid, Spain, ³La Paz University Hospital, Madrid, Spain, ⁴University Hospital Sant Joan de Deu, Barcelona, Spain, ⁵Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Clínica Universidad de Navarra, Madrid, Spain, ⁷Hospital La Fe, Valencia, Comunidad Valenciana, Spain, ⁸Ramon y Cajal Hospital, MADRID, Spain, ⁹Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ¹⁰H.U Central de Asturias, Oviedo, Spain, ¹¹Hospital de Sant Pau, Bareclona, ¹²H.U de La Merced, Sevilla, Spain, ¹³HOSPITAL UNIVERSITARIO LA PAZ, MADRID, ¹⁴H.U Virgen de Las Nieves, Granada, Spain, ¹⁵H. R. U. Malaga, Malaga, Spain, ¹⁶H.U. Virgen del Rocío, Sevilla, Spain, ¹⁷H.U de A Coruña, A Coruña, Spain, ¹⁸H.U. Canarias, Canarias, Spain, ¹⁹H.U Virgen de la Arrixaca, Murcia, Spain, ²⁰H.U. marques de Valdecilla, Santander, Spain, ²¹H.U Vall d´Hebron, Barcelona, Spain, ²²Pediatric Rheumatology Department, Taulí Hospital Universitari-Institut d'Investigació i Innovació Parc Taulí (I³PT-CERCA), Sabadell (Spain)., Sabadell, Spain, ²³H.U. La Fé, Valencia, Spain, ²⁴Hospital León, LEON, Castilla y Leon, Spain, ²⁵H.U Canarias, Canarias, Spain, ²⁶Rheumatologist, La Laguna, Spain, ²⁷H.R.U Malaga, Malaga, Spain, ²⁸Complejo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ²⁹Hospital Germans Trias i Pujol, Badalona, Spain, ³⁰H.U Ramón y Cajal, Madrid, Spain, ³¹IdISSC. HCSC, Madrid, Madrid, Spain
Background/Purpose: Antiphospholipid antibodies (aPL) have been associated with organ damage and certain features in juvenile-onset systemic lupus erythematosus (jSLE) patients. We aimed to assess the…
Abstract Number: 1106 • ACR Convergence 2025
Faster Ellipsoid Zone Loss in Hydroxychloroquine Retinopathy with Tapering versus Discontinuation: A Longitudinal Optical Coherence Tomography Study from a Single Center in Taiwan
Ko-Jen Li¹, Ting-Wei Chang², Tso-Ting Lai³, Jui-Hung Kao⁴, TING-YUAN LAN⁵, Tai-Ju Lee⁶, pei-Hsinq lai⁷, Shao-Yu Pai⁸, Chiehyu Shen⁹ and Song-Chou Hsieh¹⁰, ¹National Taiwan University Hospital, Taipei, Taiwan, ²National Taiwan University Hospital Hsinchu Branch, Taichung, Taiwan, ³Naitional Taiwan University Hospital, Taipei, Taiwan (Republic of China), ⁴Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan, Taipei, Taiwan (Republic of China), ⁵National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan, ⁶National Taiwan University Hospital Hsinchu Branch, Hsinchu City, Taiwan (Republic of China), ⁷Taipei City Hospital, Taichung, Taiwan, ⁸National Taiwan University Hospital, Taichung City, Taiwan (Republic of China), ⁹National Taiwan University Hospital, Taipei city, Taiwan, ¹⁰National Taiwan Unuversity Hospital, Taipei City, Taiwan (Republic of China)
Background/Purpose: Hydroxychloroquine (HCQ) retinopathy is a progressive, vision-threatening retinal disease. While HCQ is typically discontinued after toxicity is detected, some patients undergo tapering due to…
Abstract Number: 0981 • ACR Convergence 2025
GNTI-350: A CAR-Treg Therapy Offering Durable Immune Reset with Improved Safety for B Cell–Driven Autoimmune Diseases
Christopher Moore¹, Travis Drow², Peter Cook², Annaiz Grimm², Victoria DeVault-Nelson¹, Jennifer Mellen¹, Payam Zarin¹, Alaina Burgess¹, Maegan Hoover¹, Tingxi Guo¹, Brock McKinney², Noelle Dahl², Aesha Vakil², Brian Christin³, Gene Uenishi¹, Tiffany Chen¹, Alberto Del Rio-Espinola⁴, David Rawlings² and Tom Wickham¹, ¹GentiBio, Cambridge, ²SCRI, Seattle, ³GentiBio, Seattle, ⁴GentiBio, Basel, Switzerland
Background/Purpose: CD19 CAR T therapies have demonstrated promise in systemic lupus erythematosus (SLE) by transiently depleting B cells and resetting the immune system. However, long-term…
Abstract Number: 0927 • ACR Convergence 2025
Improved Skin Lymphatic Flow Regulates Dendritic Cells to Mediate Lymph Node Fibroblast Alterations and Immune Responses in Lupus
Mir Howlader¹ and Theresa Lu², ¹Weill Cornell Medical College, Brooklyn, NY, ²Hospital for Special Surgery, NEW YORK, NY
Background/Purpose: Lupus is a chronic autoimmune disease with a global loss of self-tolerance. Lupus patients are photosensitive where exposure to even ambient sunlight results in…
Abstract Number: 0660 • ACR Convergence 2025
Effects of Deucravacitinib on Dysregulated Autoimmune Gene Modules That Correlate With Skin Disease Severity and Treatment Response in Patients With Cutaneous Manifestations of Lupus Erythematosus: Biomarker Results From a Global, Randomized, Placebo-Controlled Phase 2 Study
J. Michelle Kahlenberg¹, Victoria Werth², Joerg Wenzel³, John Schwarz⁴, Jinqi Liu⁴ and Brandon Johnson⁴, ¹University of Michigan, Ann Arbor, MI, ²University of Pennsylvania, Philadelphia, PA, ³Department of Dermatology and Allergy, University Hospital of Bonn, Bonn, Germany, ⁴Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in moderate to severe plaque psoriasis, has demonstrated significant improvements in cutaneous manifestations…
Abstract Number: 0637 • ACR Convergence 2025
DNA Methylation Patterns Differ Between Genetically Similar Systemic Lupus Erythematosus (SLE) Patients From Peru and the U.S.
Sundus Dwidar¹, Mary Horton², Meghan Nelson³, Joanne Nititham², Richard Oppong³, Frank Donovan⁴, Jinoos Yazdany⁵, Maria Dall'Era⁶, Lisa Barcellos⁷, Heinner Guio⁸, Manuel Ugarte-Gil⁹, Lindsey Criswell² and Cristina Lanata¹⁰, ¹National Institutes of Health, Washington, ²NIH/NHGRI, Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴National Institutes of Health, Bethesda, ⁵UCSF, San Francisco, CA, ⁶Division of Rheumatology, University of California, San Francisco, CA, ⁷UC Berkeley, Berkeley, ⁸Universidad de Huanuco, Lima, Peru, ⁹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ¹⁰NIH/NHGRI, Bethesda
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that disproportionately affects individuals of Amerindian ancestry and those who self-identify as Hispanic. The term “Hispanic”…
Abstract Number: 0619 • ACR Convergence 2025
Interim Analysis of the Impact of a Recombinant Herpes Zoster Vaccine on Systemic Lupus Erythematosus: A Randomized Controlled Study on Immunogenicity, Safety and Immunosuppressor Effects
Luciana Parente Costa Seguro¹, Andrea Negrini², Sandra G Pasoto³, Nadia E Aikawa⁴, Ana C Medeiros-Ribeiro³, Eduardo Borba¹, Emily Figueiredo Neves Yuki⁵, Artur Sartori², Danieli Andrade⁶, Thiago Freitas⁷, Henrique Giardini⁷, Clovis Artur Silva⁸ and Eloisa Bonfa¹, ¹Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, Sao Paulo, Sao Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁵Faculdade de Medicina da USP, São Paulo, São Paulo, Brazil, ⁶University of Sao Paulo, São Paulo, São Paulo, Brazil, ⁷Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ⁸University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: SLE patients are at increased risk of infections, including herpes zoster (HZ). Prior studies evaluating the recombinant herpes zoster vaccine (RZV) in SLE have…
Abstract Number: 0602 • ACR Convergence 2025
Association of Systemic Lupus Erythematosus with Healthcare Resource Utilization and Healthcare Expenditures: Analysis of Nationally Representative Data, 2017-2022
Ami Vyas¹, Steven Cohen² and Christine Eisenhower², ¹University of Rhode Island, Kingston, RI, ²University of Rhode Island, Kingston
Background/Purpose: Limited information is available about the effect of systemic lupus erythematosus (SLE) on healthcare resource utilization and healthcare expenditures. The associations between SLE and…
Abstract Number: 0825 • ACR Convergence 2025
Rheum2Learn: A Randomized Trial of Virtual vs Text-Based Rheumatology Modules
Sonam Kiwalkar¹, Julianna Desmarais², Ellen Snyder³, Lisa Schroeder⁴, Marissa Meissner⁵, Noelle A. Rolle⁶, Sarah Donohue⁷, Brittany Bettendorf⁸, Ira Khanna⁹, Karen Kruzer¹⁰, Nkechi Emejuaiwe¹¹, Ibtissam Gad¹², David Leverenz¹³, Michael George¹⁴, Ashima Makol¹⁵, Floranne Ernste¹⁵ and Jilie Blaszczak¹⁶, ¹The Vancouver Clinic, Portland, OR, ²Oregon Health and Sciences University, Portland, OR, ³UNC Rheumatology, Chapel Hill, NC, ⁴Geisinger, Danville, PA, ⁵Geisinger Medical Center, Danville, PA, ⁶Medical College of Georgia at Augusta University, Evans, GA, ⁷University of Wisconsin, Madison, WI, ⁸University of Iowa, Iowa City, IA, ⁹Mount Sinai Hospital, New York, NY, ¹⁰Assistant Professor- University of Rochester, Victor, NY, ¹¹Cincinnati VA Medical Center, Cincinnati, OH, ¹²University of Michigan, Plymouth, MI, ¹³Duke University, Durham, NC, ¹⁴University of Pennsylvania, Philadelphia, PA, ¹⁵Mayo Clinic, Rochester, MN, ¹⁶University of Michigan, Ann Arbor, MI
Background/Purpose: Internal medicine (IM) residents often receive limited rheumatology training, contributing to low confidence in managing rheumatologic conditions and suboptimal performance on standardized examinations. Virtual…

« Previous Page
1
…
3
4
5
6
7
…
181
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].